ECSP099650A - Composiciones farmacéuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima 5 -reductasa y un antagonista de los receptores 1 -adrenergicos - Google Patents
Composiciones farmacéuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima 5 -reductasa y un antagonista de los receptores 1 -adrenergicosInfo
- Publication number
- ECSP099650A ECSP099650A EC2009009650A ECSP099650A ECSP099650A EC SP099650 A ECSP099650 A EC SP099650A EC 2009009650 A EC2009009650 A EC 2009009650A EC SP099650 A ECSP099650 A EC SP099650A EC SP099650 A ECSP099650 A EC SP099650A
- Authority
- EC
- Ecuador
- Prior art keywords
- enzyme
- pharmaceutical compositions
- adrenergic receptors
- combination
- reduction inhibitor
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 title 1
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 abstract 1
- 229960004607 alfuzosin Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001389 doxazosin Drugs 0.000 abstract 1
- 229960004199 dutasteride Drugs 0.000 abstract 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 abstract 1
- 229960004039 finasteride Drugs 0.000 abstract 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención está relacionada con diversas composiciones farmacéuticas que están compuestas por la combinación sinérgica de un agente inhibidor de la enzima 5 -reductasa, como lo son los principios activos: Finasterida o Dutasterida y un agente antagonista de los receptores -adrenérgicos, como lo son los principios activos: Alfuzosina o Doxazosina, mismos que se encuentran formulados en una sola unidad de dosificación para ser administrada por vía oral en forma de tabletas, las cuales están indicadas para el tratamiento de la Hiperplasia Prostática Benigna, así como para el alivio de los síntomas manifestados por dicha enfermedad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007003949A MX2007003949A (es) | 2007-04-02 | 2007-04-02 | Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima (-reductasa y un antagonista de los receptores 1 (-adrenergicos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099650A true ECSP099650A (es) | 2009-10-30 |
Family
ID=39808488
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009650A ECSP099650A (es) | 2007-04-02 | 2009-09-23 | Composiciones farmacéuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima 5 -reductasa y un antagonista de los receptores 1 -adrenergicos |
| EC2009009649A ECSP099649A (es) | 2007-04-02 | 2009-09-23 | Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009649A ECSP099649A (es) | 2007-04-02 | 2009-09-23 | Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2156836B1 (es) |
| AR (1) | AR065918A1 (es) |
| BR (1) | BRPI0809309A2 (es) |
| CL (1) | CL2008000964A1 (es) |
| CO (1) | CO6140029A2 (es) |
| EC (2) | ECSP099650A (es) |
| ES (1) | ES2656426T3 (es) |
| GT (1) | GT200900275A (es) |
| MX (1) | MX2007003949A (es) |
| WO (1) | WO2008120967A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012162776A1 (pt) * | 2011-06-03 | 2012-12-06 | Eurofarma Laboratórios S.A | Composição farmacêutica para o tratamento de hiperplasia prostática benigna |
| DE212018000251U1 (de) * | 2017-06-30 | 2020-05-12 | Antev Limited | Zusammensetzung zur Behandlung akuter Harnverhaltung |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ241979A (en) * | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
| WO2001021167A1 (en) * | 1999-09-22 | 2001-03-29 | Merck & Co., Inc. | Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein |
-
2007
- 2007-04-02 MX MX2007003949A patent/MX2007003949A/es active IP Right Grant
-
2008
- 2008-01-29 WO PCT/MX2008/000012 patent/WO2008120967A1/es not_active Ceased
- 2008-01-29 ES ES08712560.5T patent/ES2656426T3/es active Active
- 2008-01-29 EP EP08712560.5A patent/EP2156836B1/en not_active Not-in-force
- 2008-01-29 BR BRPI0809309-1A2A patent/BRPI0809309A2/pt not_active Application Discontinuation
- 2008-04-01 AR ARP080101373A patent/AR065918A1/es unknown
- 2008-04-02 CL CL2008000964A patent/CL2008000964A1/es unknown
-
2009
- 2009-09-23 EC EC2009009650A patent/ECSP099650A/es unknown
- 2009-09-23 CO CO09103767A patent/CO6140029A2/es unknown
- 2009-09-23 EC EC2009009649A patent/ECSP099649A/es unknown
- 2009-10-21 GT GT200900275A patent/GT200900275A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6140029A2 (es) | 2010-03-19 |
| EP2156836A4 (en) | 2011-01-26 |
| BRPI0809309A2 (pt) | 2014-10-14 |
| WO2008120967A1 (es) | 2008-10-09 |
| CL2008000964A1 (es) | 2009-03-20 |
| EP2156836A1 (en) | 2010-02-24 |
| AR065918A1 (es) | 2009-07-08 |
| EP2156836B1 (en) | 2017-10-18 |
| GT200900275A (es) | 2016-01-21 |
| ES2656426T3 (es) | 2018-02-27 |
| ECSP099649A (es) | 2009-10-30 |
| MX2007003949A (es) | 2009-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20130069A7 (es) | Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis | |
| ES2526606T3 (es) | Composición farmacéutica sólida que comprende amlodipina y losartán | |
| PA8746901A1 (es) | Formulaciones de un compuesto en forma de polvo seco y usos de estas | |
| DK2321321T3 (da) | Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister | |
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| PA8849701A1 (es) | Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BRPI0912112B8 (pt) | composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica | |
| PE20150773A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilefrina | |
| UY28517A1 (es) | Nueva combinación | |
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos | |
| TR200900879A2 (tr) | Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler | |
| GT200500026A (es) | Derivados de beta-aminoacidos como inhibidores del factor xa. | |
| PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
| ECSP099650A (es) | Composiciones farmacéuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima 5 -reductasa y un antagonista de los receptores 1 -adrenergicos | |
| AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
| ECSP099734A (es) | Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| AR065917A1 (es) | Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor | |
| CO6640306A2 (es) | Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso | |
| CO2022011987A2 (es) | Usos y composiciones a base de polifenoles para mejorar la biodisponibilidad oral del hidroxitirol | |
| UY29989A1 (es) | Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones | |
| UY31096A1 (es) | Composiciones farmacéuticas que comprenden la combinacion de un agente derivado hidrogenado de lipstatina y un agente inhibidor de hmg-coa reductasa | |
| AR067465A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico | |
| AR072871A1 (es) | Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica | |
| MX2024001154A (es) | Tratamiento del eczema de manos con baricitinib. |